Premier Alternatives

BlueWhale Bio

Philadelphia, PA · Founded 2022 · Privately Held (backing)

Developer of a cell-based therapeutic platform intended to overcome bottlenecks in gene therapy manufacturing. BlueWhale Bio is based in Philadelphia, PA and was founded in 2022. It was valued at $52 million at its early-stage round in Oct 2025, the last priced event on record. It has raised $23 million across 1 recorded round; the latest was a $5 million early-stage round in Oct 2025.

PMV mark · valuation
$52.0M
Oct 2026
Priced at
its early-stage round
Oct 2025
Total raised
$23.0M
Last round
Early Stage VC
Oct 2025

BlueWhale Bio key facts

as of Oct 2026
  • Developer of a cell-based therapeutic platform intended to overcome bottlenecks in gene therapy manufacturing.
  • BlueWhale Bio is valued at approximately $52.0M as of Oct 2026, set at its early-stage round, Oct 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $23.0M across 1 recorded rounds; the latest was Early Stage VC ($5.0M) in Oct 2025.
  • Notable investors include Hillhouse Investment Group, Marshall Wace, Novalis LifeSciences, Danaher Ventures, Penn Center for Innovation.
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$52.0M

Valued at $52.0M at its early-stage round, Oct 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of BlueWhale Bio with a free account
  • ·Watch BlueWhale Bio: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

BlueWhale Bio funding rounds

1 rounds
Oct 2025Early Stage VC$5.0MSEC filing▮
Full funding history →

BlueWhale Bio valuation

BlueWhale Bio was valued at $52 million at its early-stage round in Oct 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has BlueWhale Bio raised?

BlueWhale Bio has raised $23 million in total; 1 of its rounds is on record. The largest on record was a $5 million early-stage round in Oct 2025.

BlueWhale Bio investors

5 investors are on record for BlueWhale Bio, including Hillhouse Investment Group, Marshall Wace, Novalis LifeSciences and Danaher Ventures. The early-stage round in Oct 2025 drew 1 investor.

About BlueWhale Bio

Developer of a cell-based therapeutic platform intended to overcome bottlenecks in gene therapy manufacturing. The company's platform utilizes Synecta Activation, which facilitates cell-derived nanoparticles to mimic the physiological activation of immune cells and superior cell quality achieved through a simplified workflow that is faster, robust, and cost-effective, enabling patients to attain effective cancer treatment plans.

Sector
Healthcare
HQ
Philadelphia, PA, United States
Founded
2022
Employees
31
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.